$APVO
Aptevo Therapeutics Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122837 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $3.103M
YoY Change -20.17%
% of Gross Profit
Depreciation & Amortization $84.00K
YoY Change -30.58%
% of Gross Profit
Operating Expenses $3.103M
YoY Change -20.17%
Operating Profit -$5.213M
YoY Change -20.55%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $112.0K
YoY Change -50.66%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$5.101M
YoY Change -19.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.48
COMMON SHARES
Basic Shares Outstanding 18.51M 9.420M
Diluted Shares Outstanding 10.55M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.753M
YoY Change -59.43%
Cash & Equivalents $7.753M
Short-Term Investments
Other Short-Term Assets $624.0K
YoY Change -3.85%
Inventory
Prepaid Expenses $1.635M
Receivables
Other Receivables
Total Short-Term Assets $10.01M
YoY Change -52.61%
LONG-TERM ASSETS
Property, Plant & Equipment $614.0K
YoY Change -39.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.134M
YoY Change -14.48%
TOTAL ASSETS
Total Short-Term Assets $10.01M
Total Long-Term Assets $5.134M
Total Assets $15.15M
YoY Change -44.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.532M
YoY Change -11.7%
Accrued Expenses $1.622M
YoY Change -27.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.882M
YoY Change -13.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $14.00K
YoY Change -99.75%
Total Long-Term Liabilities $14.00K
YoY Change -99.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.882M
Total Long-Term Liabilities $14.00K
Total Liabilities $10.73M
YoY Change -13.58%
SHAREHOLDERS EQUITY
Retained Earnings -$241.3M
YoY Change 10.9%
Common Stock $245.7M
YoY Change 5.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.420M
YoY Change
Total Liabilities & Shareholders Equity $15.15M
YoY Change -44.17%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.101M
YoY Change -19.47%
Depreciation, Depletion And Amortization $84.00K
YoY Change -30.58%
Cash From Operating Activities -$5.222M
YoY Change -16.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.909M
YoY Change 13.06%
NET CHANGE
Cash From Operating Activities -5.222M
Cash From Investing Activities
Cash From Financing Activities 4.909M
Net Change In Cash -313.0K
YoY Change -83.48%
FREE CASH FLOW
Cash From Operating Activities -$5.222M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001671584
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37746
dei Entity Registrant Name
EntityRegistrantName
APTEVO THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1567056
dei Entity Address Address Line1
EntityAddressAddressLine1
2401 4th Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1050
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98121
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
838-0500
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
APVO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18512084
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7753000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16904000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1635000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1473000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
624000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
689000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
10012000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19066000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
614000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
895000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4520000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4881000
CY2024Q3 us-gaap Assets
Assets
15146000
CY2023Q4 us-gaap Assets
Assets
24842000
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3532000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3984000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
922000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2098000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1428000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1142000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5882000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7224000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4830000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5397000
CY2024Q3 us-gaap Liabilities
Liabilities
10726000
CY2023Q4 us-gaap Liabilities
Liabilities
12621000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17050536
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17050536
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
442458
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
442458
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
82000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
61000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
245603000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235607000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241265000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-223447000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
4420000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12221000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15146000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24842000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3103000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3887000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10498000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13516000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2110000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2674000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7722000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8978000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5213000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6561000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18220000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22494000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
112000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
227000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
402000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
390000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
9650000
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5101000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6334000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-17818000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-12454000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
946000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5101000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6334000
us-gaap Net Income Loss
NetIncomeLoss
-17818000
us-gaap Net Income Loss
NetIncomeLoss
-11508000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.48
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-22.16
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-60.84
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.48
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-22.16
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-60.84
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-22.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-56.22
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-22.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-56.22
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10548470
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
285886
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3554796
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
204694
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10548470
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
285886
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3554796
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
204694
us-gaap Profit Loss
ProfitLoss
-17818000
us-gaap Profit Loss
ProfitLoss
-11508000
us-gaap Share Based Compensation
ShareBasedCompensation
1141000
us-gaap Share Based Compensation
ShareBasedCompensation
1835000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
451000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
10000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-2500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
96000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-299000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
361000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
311000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1341000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
129000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
554000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
504000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18026000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6477000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3467000
apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
1000
apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
8000
apvo Proceeds From Issuance Of Common Stock And Prefunded Warrants
ProceedsFromIssuanceOfCommonStockAndPrefundedWarrants
8879000
apvo Proceeds From Issuance Of Common Stock And Prefunded Warrants
ProceedsFromIssuanceOfCommonStockAndPrefundedWarrants
6427000
apvo Payments In Lieu Of Fractional Shares
PaymentsInLieuOfFractionalShares
3000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8875000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2952000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9151000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3525000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16904000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22635000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7753000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19110000
apvo Warrant Modification Incremental Value
WarrantModificationIncrementalValue
472000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12221000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
-3000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
719000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6834000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6103000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3970000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
273000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5883000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4463000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4437000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
472000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5101000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
4420000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17974000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-8000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1602000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
915000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
2773000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
23256000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-2000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
482000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
465000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7948000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16253000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1199000
CY2023Q3 apvo Proceeds From Issuances Of Pre Funded Warrants
ProceedsFromIssuancesOfPreFundedWarrants
3145000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
455000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6334000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14718000
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5800000
CY2024Q3 apvo Common Stock Issuance Costs
CommonStockIssuanceCosts
1300000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
500000
CY2024Q3 apvo Number Of Technology Platforms
NumberOfTechnologyPlatforms
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the unaudited condensed financial statements and accompanying notes. Estimates are used for, but not limited to, clinical accruals, useful lives of equipment, commitments and contingencies, stock-based compensation, and incremental borrowing rate (IBR) used for our lease. Given the global economic and geopolitical climate, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</span></p>
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
523000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
946000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
1900000
apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
2000000
apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5800000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13200000
apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2024Q3 us-gaap Cash
Cash
1966000
CY2023Q4 us-gaap Cash
Cash
3733000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
5787000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13171000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7753000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16904000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
297000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
297000
us-gaap Operating Lease Cost
OperatingLeaseCost
890000
us-gaap Operating Lease Cost
OperatingLeaseCost
890000
CY2024Q3 us-gaap Lease Cost
LeaseCost
297000
CY2023Q3 us-gaap Lease Cost
LeaseCost
297000
us-gaap Lease Cost
LeaseCost
890000
us-gaap Lease Cost
LeaseCost
890000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4520000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4881000
us-gaap Operating Lease Payments
OperatingLeasePayments
1032000
us-gaap Operating Lease Payments
OperatingLeasePayments
803000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4800000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
700000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5600000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
700000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M29D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
apvo Reverse Stock Split
ReverseStockSplit
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8. Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, we held a Special Meeting of the Stockholders (the "Special Meeting") at which our stockholders approved a series of alternate amendments to the Amended and Restated Certificate of Incorporation to effect, at the option of our Board of Directors (the "Board"), a reverse split of Aptevo's common stock at a ratio ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_828d7325-d1b1-41f0-a12a-9bb5cce58328;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-15</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cc43f9be-b9ce-4d40-a47d-e53db0b70846;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-44</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board in its sole discretion following the Special Meeting. The specific </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_14e0d739-0292-4efb-b9c4-9429a63f4f2c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-44</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse split ratio was subsequently approved by the Board on February 27, 2024. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 5, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-44 reverse stock split of the Company's outstanding common stock (the "Reverse Stock Split").</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Reverse Stock Split became effective on March 5, 2024 at 5:01 p.m. Eastern Time, and our common stock began trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on March 6, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adjusted all common stock and stock equivalent figures retroactively in this Form 10-Q for all periods presented to reflect the Reverse Stock Split.</span></p>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On March 5, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-44 reverse stock split of the Company's outstanding common stock (the "Reverse Stock Split").
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5101000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6334000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-17818000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-12454000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
946000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5101000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6334000
us-gaap Net Income Loss
NetIncomeLoss
-17818000
us-gaap Net Income Loss
NetIncomeLoss
-11508000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.48
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-22.16
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-60.84
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.48
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-22.16
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-60.84
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
4.62
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.62
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-22.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-56.22
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-22.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-56.22
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10548470
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
285886
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3554796
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
204694
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10548470
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
285886
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3554796
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
204694
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
697220
CY2023Q4 apvo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
20.36
CY2023 apvo Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y11M26D
apvo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
35661432
apvo Class Of Warrant Or Right Issued Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
0.58
apvo Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y10M6D
apvo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
7967
apvo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
800.8
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36350685
CY2024Q3 apvo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.38
apvo Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y9M18D
CY2024Q3 apvo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
18168865
CY2024Q3 apvo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
0.54
apvo Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P4Y7M9D
CY2024Q3 apvo Class Of Warrant Or Right Expected Dividend Yield
ClassOfWarrantOrRightExpectedDividendYield
0
CY2023Q3 apvo Class Of Warrant Or Right Expected Dividend Yield
ClassOfWarrantOrRightExpectedDividendYield
0
apvo Class Of Warrant Or Right Expected Dividend Yield
ClassOfWarrantOrRightExpectedDividendYield
0
apvo Class Of Warrant Or Right Expected Dividend Yield
ClassOfWarrantOrRightExpectedDividendYield
0
CY2024Q3 apvo Class Of Warrant Or Right Expected Volatility Rate
ClassOfWarrantOrRightExpectedVolatilityRate
1.1324
CY2023Q3 apvo Class Of Warrant Or Right Expected Volatility Rate
ClassOfWarrantOrRightExpectedVolatilityRate
1.0357
apvo Class Of Warrant Or Right Expected Volatility Rate
ClassOfWarrantOrRightExpectedVolatilityRate
1.1216
apvo Class Of Warrant Or Right Expected Volatility Rate
ClassOfWarrantOrRightExpectedVolatilityRate
1.0357
CY2024Q3 apvo Class Of Warrant Or Right Risk Free Interest Rate
ClassOfWarrantOrRightRiskFreeInterestRate
0.0527
CY2023Q3 apvo Class Of Warrant Or Right Risk Free Interest Rate
ClassOfWarrantOrRightRiskFreeInterestRate
0.0533
apvo Class Of Warrant Or Right Risk Free Interest Rate
ClassOfWarrantOrRightRiskFreeInterestRate
0.0523
apvo Class Of Warrant Or Right Risk Free Interest Rate
ClassOfWarrantOrRightRiskFreeInterestRate
0.0418
CY2024Q3 apvo Class Of Warrant Or Right Expected Average Life Of Warrants
ClassOfWarrantOrRightExpectedAverageLifeOfWarrants
P5Y
CY2023Q3 apvo Class Of Warrant Or Right Expected Average Life Of Warrants
ClassOfWarrantOrRightExpectedAverageLifeOfWarrants
P5Y
apvo Class Of Warrant Or Right Expected Average Life Of Warrants
ClassOfWarrantOrRightExpectedAverageLifeOfWarrants
P3Y3M
apvo Class Of Warrant Or Right Expected Average Life Of Warrants
ClassOfWarrantOrRightExpectedAverageLifeOfWarrants
P3Y3M
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
455000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1141000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1835000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
73.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 apvo Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 apvo Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false

Files In Submission

Name View Source Status
apvo-20240930_htm.xml Edgar Link completed
0000950170-24-122837-index-headers.html Edgar Link pending
0000950170-24-122837-index.html Edgar Link pending
0000950170-24-122837.txt Edgar Link pending
0000950170-24-122837-xbrl.zip Edgar Link pending
apvo-20240930.htm Edgar Link pending
apvo-20240930.xsd Edgar Link pending
apvo-ex31_1.htm Edgar Link pending
apvo-ex31_2.htm Edgar Link pending
apvo-ex32_1.htm Edgar Link pending
apvo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending